biote (NASDAQ:BTMD - Get Free Report) is scheduled to be announcing its earnings results after the market closes on Tuesday, November 12th. Analysts expect the company to announce earnings of $0.09 per share for the quarter. biote has set its FY 2024 guidance at EPS.Individual that wish to register for the company's earnings conference call can do so using this link.
biote (NASDAQ:BTMD - Get Free Report) last announced its quarterly earnings data on Thursday, August 8th. The company reported $0.14 EPS for the quarter, beating the consensus estimate of $0.09 by $0.05. The firm had revenue of $49.17 million during the quarter, compared to analyst estimates of $50.40 million. biote had a net margin of 3.67% and a negative return on equity of 20.92%. On average, analysts expect biote to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.
biote Stock Up 1.0 %
Shares of NASDAQ:BTMD traded up $0.05 during trading on Tuesday, hitting $5.22. 77,304 shares of the stock traded hands, compared to its average volume of 161,659. The company has a fifty day moving average price of $5.57 and a two-hundred day moving average price of $6.27. The company has a market cap of $283.03 million, a price-to-earnings ratio of 30.71 and a beta of 0.94. biote has a 52-week low of $3.65 and a 52-week high of $8.44.
About biote
(
Get Free Report)
biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support.
See Also
Before you consider biote, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and biote wasn't on the list.
While biote currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
